News Release

Action needed to stop 'disease mongering'

Selling sickness: the pharmaceutical industry and disease mongering BMJ Volume 324, pp 886-91

Peer-Reviewed Publication

BMJ Group

A lot of money can be made from telling healthy people they’re sick despite clear conflicts of interest. Pharmaceutical companies sponsor disease definitions and promote them to prescribers and consumers. In this week’s BMJ researchers give examples of “disease mongering” and suggest how to prevent the growth of this practice.

Some forms of medicalising ordinary life may be better described as “disease mongering” – extending the boundaries of treatable illness to expand markets for new products.

Disease mongering can include turning ordinary processes or ailments into medical problems. For example, around the time that Merck’s hair growth drug finasteride (Propecia) was first approved in Australia, leading newspapers featured new information about the emotional trauma associated with hair loss, say the authors.

Disease mongering can also include seeing mild symptoms as serious, and treating personal problems as medical ones: A senior Roche official tells the authors that company promotion exaggerated the level of social phobia in Australia.

Risks are increasingly portrayed as diseases, according to the authors, citing the example of corporate backed promotional activities for osteoporosis which attempt to persuade millions of healthy women worldwide that they are sick.

Although these observations of disease mongering are selective and preliminary, the authors believe that more could be done to expose and reduce misleading “wonder drug” stories in the media, which help to facilitate so much disease mongering. They

###


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.